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The phytohemagglutinins (PHAP)' derived from Phaseolus uulgaris consist of a family of
five isomitogens made up of varying proportions of two similar, but nonidentical subunits
designated "L" and "R" (1) . L-PHAP is a potent mitogen and leukoagglutinin which
contains four L subunits, and which lacks hemagglutinating and red blood cell (RBC)
binding properties (2, 3) . H-PHAP is a mixture of three isomitogenic proteins of
increasingly positive charge (4), the subunit structure of which may be represented as
2L-2R, 1L-3R, and 411, respectively (1, 5) . These three isomitogens are also capable of
binding to lymphocytes, and they can evoke a lymphocyte mitogenic response in
proportion to their L-subunit content (4) . In contrast to L-PHAP, however, they can bind
to and agglutinate RBC by virtue of their R-subunit affinity for glycoprotein structures
present on the RBC membrane (1-3, 5, 6) . Furthermore, H-PHAP can bind to and
precipitate with a variety of serum glycoproteins which possess glycopeptide structures
resembling those found on RBC, whereas L-PHAL lacks this ability (4, 7) . Presumably,
the ability to interact with serum glycoproteins is bestowed upon H-PHAP molecules by
virtue of their R-subunit binding sites (1) .
One serum glycoprotein, fetuin, possesses oligosaccharide subunits similar in
structure to those present on red cells which form the attachment site for
H-PHAP (6) . Both fetuin and its glycopeptide can inhibit H-PHAP-induced
hem agglutination (6, 8) . Fetuin is also capable of reversing the binding of
H-PHAP to lymphocyte membranes and of inhibiting the ability of H-PHAP to
stimulate lymphocyte amino acid uptake and DNA synthesis (9) . This report
examines the ability of H- and L-PHAP to bind to or precipitate with fetuin, as
well as the ability of fetuin to inhibit lymphocyte transformation by these and
other mitogenic phytoproteins.
* Operated by the University of Chicago for the United States Atomic Energy Commission.
Abbreviations used in this paper; ATS, antithymocyte antiserum; BSA, bovine serum albumin;
CON-A, concanavalin A; IRA, immunoregulatory a-globulin; MLC, mixed lymphocyte culture; PBS,
0.15 M NaCl, 0.01 M PO  pH 7 .0; PHAP, phytohemagglutinin; PWM, pokeweed mitogen; RBC,
red blood cell.
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Materials and Methods
The isolation of H- and L-PHAP, and the procedure used for their radioiodination have been
described previously (2, 5) . Pokeweed mitogen (PWM) and concanavalin A (CON-A) (10) were
employed as mitogens in certain experiments. Antithymocyteantiserum (ATS) was prepared in New
Zealandwhiterabbits by five or sixsuccessive weekly i.v . injections of saline suspension of 108human
fetal thymocytes derivedfrom 16-20-wk-old aborted fetuses. 1 wk after the last injection, the rabbits
were bled ; the isolated serum was heat inactivated at 56°C for 30 min and stored frozen at -20°C.
Detailed descriptions of the methods used for isolating and culturinglymphocytes and determining
their incorporation of [2-"C]thymidine into DNA have been provided (2, 5). 4-ml replicate cultures
containing 1.5-2 x 108 lymphocytes, free of RBC or platelet contamination, in RPMI-1640
supplemented with L-glutamine, antibiotics, and 12.5% human AB serum (in the case of ATS, heat-
inactivated AB serum was employed) or autologous plasma were utilized in most experiments . In
certain experiments, noted in the text, a 1-ml culture system was employed.
Peripheral blood mononuclear cells for use in one-way mixed lymphocyte cultures (MLC) were
isolated by a Ficoll-Hypaque technique (9). 4-ml triplicate cultures containing 2 x 108responding
cells and 1.0 x 108 mitomycin-treated stimulating cellswere incubated for 5 days before the addition
of [2-"C]thymidine and harvesting 16 h later (10).
Fetuin (Spiro method), purchasedfrom Grand Island Biological Co. (Grand Island,N. Y.) (cat. no.
9185), wasdissolved in water at aconcentration of50 mg/ml and dialyzed vs.0.15MNaCl before use.
A maximum of 10 mg of fetuin in 200ml of 0.15 M NaCl wasaddedto individual lymphocyte cultures
just before the addition of mitogen (maximum final fetuin concentration, 2.5 mg/ml) . Fetuin was
radioiodinated with 1251 by the iodine monochloride method (11). Thefinal preparation hadaspecific
activity of approximately 1,000 cpm/ug, of which 95% was precipitable by 50% (NH,),SO,.
The effect offetuin on lymphocyte survival and viabilitywasexamined by incubating lymphocytes
in the presence of 2.5 mg/ml fetuin under conditions identical to those used for mitogen-induced
transformation. After 88 h incubation, cell counts were performed, andthe proportion of remaining
cells which were viable was determined by the trypan-blue exclusion technique.
The uptake of ' 251-labeled fetuin by lymphocytes was studied in both short- and long-term
experiments. Mononuclear cells, free of platelets and RBC, were isolated by the Ficoll-Hypaque
method, and half of the cells so obtained were passed over a nylon column to deplete the monocyte
population. 5 million cells from each cell isolate were suspended in 1.2 ml tissue culture medium
devoid of protein save for 2.5 mg/ml [1251]fetuin and incubated at 37°C for 30 min. The glass tubes
(including controls lacking any cells, to correct for nonspecific adsorbtion) were washed five times
with 4 ml medium. After the addition of 2 ml medium, all tubes were monitored for residual
radioactivity. To examine the interaction between fetuin and human lymphocytes over longer time
periods, 4 million lymphocytes were cultured under conditions identical to those used to study
mitogen-induced lymphocyte transformation . All culture tubes contained 2.25 mg/ml cold fetuin
together with 0.25 mg/ml [1a1I]fetuin, and some received 5 ug/ml L-PHAP at zero time; cell-free
control tubes were also included. At 1, 18, 42, and 66 h appropriate tubes were removed from
incubation, and afterfive 4-ml washes, the culture tubes were subjected to scintillation counting.
The ability of fetuin to precipitate with H- and L-PHAP in agar gel was determined by the
Ouchterlony double diffusion technique (4). Formation of soluble complexes between the PHAP
mitogens and fetuin was examined by gel diffusion chromatography (12) . Approximately 50 jug of
[1251]H- or L-PHAP were mixed with 20 mg fetuin, or with 20 mg crystalline bovine serum albumin
(BSA) in a total volume of 0.8 ml 0.15 M NaCl, 0.01 M PO pH 7.0 (PBS). The mixture, which
contained 10% sucrose, was entered into a 1.5 x 100-cm column of Biogel A 0.5 M, 200-400 mesh
(Bio-Rad Laboratories, Richmond, Calif.) and eluted by upward-flow chromatography in 3.0-ml
fractions at aflow rate of 7-8ml/h. Chromatography was carried out at room temperature, and0.01%
sodium azide in PBS was used as the eluting buffer. [1251]H-PHAP, [1251]L-PHAP, BSA, and fetuin
were chromatographedseparately on several occasions. In addition, a mixture of 50 ug [1251]L-PHAP
and 10 mg unlabeled L-PHAP was studied by this technique. The void volume of the column was
determined by means of a dextran blue marker, and the column was further calibrated with an IgG
myeloma protein (mol wt 155,000) and horse heart cytochrome c (mol wt 12,400). Elution fractions
were monitored for 1251 in a gamma counter (model 1095, Nuclear-Chicago Corp., Des Plaines, 111 .),244
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and for protein, cytochrome c, or dextran blue, by absorbancy at 280, 407, or 674 nm, respectively, as
required .
Results
H-PHAP was capable of precipitating with fetuin in agar gel, whereas L-PHAP
lacked this ability when tested against a wide range of fetuin concentrations (Fig .
1) . Within 3-1/2 h, precipitin lines formed between H-PHAP and fetuin at the
higher concentrations employed, but these lines had disappeared after a further
17 h of incubation . This phenomenon, reminiscent of the dissolution of
antigen-antibody aggregates in the presence of excess antigen, suggested the
possibility of the formation of soluble complexes between fetuin and H-PHAP .
We therefore undertook a gel chromatographic analysis of the reaction between
Fig. 1 .
￿
Ouchterlony analysis of the interaction between fetuin and the PHAP mitogens . The
PHAP mitogens were placed in the center wells at a concentration of 1.6 mg/ml. The periph-
eral wells contained fetuin at the following concentrations (mg/ml) ; (a) 50 ; (b) 25 ; (c) 12 .5 ;
(d) 6.3 ; (e) 3.1. (1) H-PHAP, 20.5 h incubation ; (2) L-PHAP, 20 .5 h incubation ; (3) H-PHAP,
3.5 h incubation.
['251]H- and L-PHAP and a 400-fold excess (wt/wt) of fetuin . The results of these
studies are shown in Fig . 2 . Both [" 5I]H-PHAP and [' 2511L-PHAP emerged from
the column with a peak at fraction 25, indicating an apparent mol wt of
approximately 110,000.2 Their behavior was not altered by cochromatography
with dextran blue or 20 mg BSA or, in the case ofL-PHAP, with a 200-fold excess
of unlabeled mitogen . Fetuin (not shown) displayed anomalous behavior on gel
chromatography (15) and also emerged with an apparent mol wt of 110,000 at
tube 25 . No alteration in the pattern of fetuin elution could be seen in the
presence of 1/400 its weight of either PHAP mitogen. The behavior of H-PHAP
was strikingly altered in the presence of fetuin, however, and over 70% of the
radioactively labeled material recovered was shifted to an apparent mol wt of
350,000 or greater (tubes 16-18) . Thus, a minimum estimate of the composition
2Gel diffusion chromatography has previously been noted to underestimate the true mol wt
(136,000) ofPHAP isomitogens (2, 13, 14).90
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Fig. 2. The behavior of ['Z$IIL- and H-PHAP (50 jug) when chromatographed on Biogel A
0.5 M, either alone or in the presence of a 400-fold excess (wt/wt) of fetuin. V., void volume.
of soluble complexes formed between fetuin and H-PHAP would suggest a 2:1
fetuin :H-PHAP molecular ratio; the majority of these complexes were probably
larger. Only 5% of the radiolabeled H-PHAP emerged in its normal position,
indicating that >90% H-PHAP was involved in soluble complex formation with
fetuin. These estimates are made reasonable by the observation that the total
amounts of H-PHAP recovered from the column (fractions 1-40) in the presence
of, or absence of fetuin were similar, namely, 86 .5% and 827%, respectively.
The behavior of ["'I ]L-PHAP in the presence of a 400-fold excess of fetuin was
quite different. Approximately 7% of the recovered L-PHAP was shifted to a
position consonant with a mol wt of >-_290,000 (tubes 16-19) . The major elution
peak emerged at tube 24, a position which is equivalent to a mol wt of
approximately 125,000-130,000, indicating that the interaction between L-PHAP
and fetuin was very much weaker than that between H-PHAP and fetuin, and
was insufficient to sustain even a 1:1 molecular association between the two
proteins. Again, the total recovery of L-PHAP in tubes 1-40 was not altered
whether or not fetuin was present (74.5zE5 without vs . 78% with fetuin). Thus
H-PHAP is indeed capable of forming soluble complexes with fetuin, whereas the
affinity of L-PHAP for fetuin is very much lower and any molecular complexes
which form dissociate rapidly.
We have been able to confirm previous observations concerning the ability of246
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fetuin to inhibit H-PHAP-induced lymphocyte transformation (9) (Table 1) .
Despite L-PHAP's much lower affinity for fetuin, the ability of L-PHAP to
transform lymphocytes was also markedly inhibited by fetuin at a concentration
of 2.5 mg/ml, and to a notable, but significantly less profound degree than for
H-PHAP, at a concentration of 1.25 mg/ml. In agreement with observations by
Mendelsohn et al . (9), we have found that fetuin is not nonspecifically toxic to
lymphocytes at these concentrations since the amount of DNA synthesis in
unstimulated control lymphocytes was not depressed by fetuin, and since the
ability of fetuin to depress lymphocyte DNA synthesis in a single lymphocyte
preparation at a given fetuin concentration varied with different mitogens
(Tables I and 11). In addition, long-term incubation of human lymphocytes in the
presence of 2.5 mg/ml fetuin does not significantly reduce either the number of
TABLE I
The Ability of Fetuin to Inhibit L- and H-PHAP-Induced Lymphocyte Transformation
%Inhibition
Exp.
￿
2.5 mg/ml fetuin
￿
1.25 mg/mlfetuin
In each experiment a single preparation of lymphocytes was used in 4-ml cultures . The greater
inhibition of lymphocyte transformation by fetuin at 2.5 vs. 1.25 mg/ml for both L- and H-PHAP is
highly significant (P values < 0.001 and < 0.01, respectively) .
* Used at a concentration of 4kg/ml.
$Comparison between L- and H-PHAP at each fetuin concentration.
cells remaining in culture nor their viability as measured by trypan-blue
exclusion (Table III) .
We have also confirmedthe capacity of increasing doses of H-PHAP to cause a
partial reversal of the inhibitory effects of fetuin on H-PHAP-stimulated
lymphocyte transformation (9). When increasing doses of L-PHAP were em-
ployed in a similar fashion, however, a paradoxical effect was noted. Increments
in L-PHAP concentration not only failed to overcome the inhibitory effects of
fetuin, but led as well to an increase in its inhibitory action (Table IV). On
repeated examinations, this result was most striking at a fetuin concentration of
1.25 mg/ml, where the increase in fetuin inhibition at higher L-PHAP doses
achieved a high level of statistical significance (Fig. 3) .
Although we have not made any detailed studies of the physical interaction
between CON-A or PWM and fetuin, we have demonstrated that the presence of
L-PHAP* H-PHAP* L-PHAP* H-PHAP*
1 64 98.8 7 73.2
2 78.9 98.5' 45.7 76.2
3 97.7 99 .7 49.6 95.5
4 90.6 97 .2 26.4 65.5
5 94.6 100 21.4 77.4
Mean 85.2 98 .9 30 77.6
SD 113.8 f1.1 117.7 111.1
P values$ P < 0.1 >0.05 P < 0.001STANLEY YACHNIN
TABLE II
A Comparison of the Ability ofFetuin to Inhibit Lymphocyte Transformation Induced by
a Variety of Phytomitogens
A single lymphocyte preparation was employed throughout in 4-ml cultures.
* Compared with the amount of DNA synthesis observed in the absence of fetuin.
TABLE III
The Effect of Varying Fetuin Concentrations on Lymphocyte Survival (% ofStarting Cell
Numbers) and Lymphocyte Viability (Trypan-Blue Exclusion), after 88-h Culture in
the Absence of Mitogens
Fetuin concentration (mg/ml)
247
Mean-LSD
￿
62.8 t 27.7
￿
91.4 1 4.1
￿
59.0 t 23.6
￿
90.6 .:E 3.7
￿
59.3 t 23.3
￿
83.5 t 10.7
￿
57.5 t 26.8 72.7 t 18.1
There is no significant difference in either parameter between control and fetuin-exposed lymphocytes at any fetuin
concentration.
fetuin can also inhibit the ability of lymphocytes to synthesize DNA when these
mitogens are employed (Table II). In addition, fetuin proved to be a potent
inhibitor of ATS-induced lymphocyte transformation (Table V) as well as of the
lymphocyte DNA-synthetic response in the one-way MLC (Table VI).
Attempts to demonstrate irreversible association between lymphocytes and
Mitogen (dose) Fetuin
mg/ml
(2-14C]thymidine
incorporation
(mean t SD)
cpm
DNA synthesis
inhibition
%
Pvalues
L-PHAP (4 gg/ml) 0 2,845 1 95 - -
1.25 2,236 t 88 21.4 < .Ol*
2.5 154 t 190 94.6 < .O1*
H-PHAP (4,ug/ml) 0 2,237 1 261 - -
1.25 505-+ 133 77.4 <0.01*
2.5 0 100 -
PWM (0.5 jag/ml) 0 1,987 t 39 - -
1.25 1,542 t 98 22.4 <0.01*
2.5 339 t 162 83 <0.01*
CON-A (12 .5,m/ml) 0 1,329 t 320 - -
1.25 486 t 180 63.5 <0.02*
2.5 31 t 54 98 <0.01*
Exp. 0
Surviving
cells viable
0.63
Surviving
cells Viable
1.25
Surviving
cells Viable
2.5
Surviving
cells
viable
1 29 92 41.9 89 54.8 91.5 29.7 66
2 100 91 .5 100 96.5 100 92 100 94.5
3 71 97.5 48.4 91 51.6 66 64.5 46
4 42.9 86 46.8 86.5 40.7 81.5 44.5 80
5 71.3 90 57.8 90 49.6 86.5 48.7 77248
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TA13LE IV
The Effect of Increasing Mitogen Dose on the Bility of Fetuin to Inhibit L- and
H-PHAP-Induced Lymphocyte Transformation
A separate preparation of lymphocytes was employed for each mitogen. In this experiment, a 1-ml
culture system containing 1 .5-2 x 108 lymphocytes was used.
(1251 ]fetuin were unsuccessful . Fetuin neither binds to, nor is ingested by,
lymphocytes to any significant extent, whether the exposure of lymphocytes to
fetuin occurs over a short or long period in tissue culture; addition ofL-PHAP in
optimum mitogenic doses did not alter this result (Table VII).
Discussion
The evidence for a strong physical interaction between fetuin and H-PHAP is
persuasive; the two proteins can coprecipitate in agar gel, and the dissolution of
Mitogen Dose Fetuin
[2-"C]thymidine
incorporation
(mean t SD)
DNAsynthesis
inhibition
mg/ml cpm %
H-PHAP 4.6 - 22,057 :j- 187 -
1.25 6,935 t 1,050 68.6
2.5 462 t 75 97.9
7.7 - 21,890 t 737 -
1.25 12,189 t 24 44.3
2.5 693 t 266 96.8
15.4 - 22,803 f 4,224 -
1 .25 19,293 t 392 15.4
2.5 1,328 t 229 94.2
30.8 - 19,914 t 1,027 -
1.25 18,101 f 943 9.1
2 .5 1,490 t 202 92.5
L-PHAP 4.6 - 4,397 t 839 -
1 .25 5,053 f 1,300 0
2.5 1,415 t 874 67.8
7 .7 - 4,914 f 311 -
1.25 3,833+ 231 22
2 .5 905 t 182 81.6
15 .4 - 5,252 t 166 -
1.25 3,388 t 474 35.5
2.5 578 t 200 90.1
30.8 - 4,833 t 178 -
1.25 1,950 t 466 59.6
2.5 120 t 195 97.5z
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TABLE V
--+ H-PHAP CONTROL
o---o H-PHAP + FETUIN
FRACTION NO.
Fig. 3.
￿
The effect of increasing mitogen concentrations on the inhibition of PHAP-induced
lymphocyte transformation by fetuin. A total of 10 different experiments (five H-PHAP,
five L-PHAP) utilizing different lymphocyte preparations in a 1-ml culture system are repre-
sented. At a fetuin concentration of 1 .25 mg/ml (A) the following statistical comparisons were
made: a vs. b, P < 0.05, bvs. c, P< 0.05; b vs. d, notsignificant; b vs. e, P< 0.01 . Similar sta-
tistical comparisons at a fetuin concentration of 2.5 mg/ml (B) revealed no significant differ-
ences.
The Inhibition of A TS-Induced Lymphocyte Transformation by Fetuin
* Compared with the amount of DNA synthesis observed in the absence of fetuin.
$NS, not significant.
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ATS
dose
Fetuin
(mg/ml)
[2-14C]thymidine
incorporation
(mean f SD)
DNAsynthesis
inhibition
Pvalues
Al mg/ml cpm %
20 0 22,478 f 5,343 - -
1 .25 16,335 4,662 27.3 NS$
2.50 607 t 686 97.3 <0.01
50 0 49,506 f 3,974 - -
1 .25 6,087 f 3,537 87.7 <0.001
2.50 1,934t 1,675 96.1 <0.001250
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TABLE VI
The Effect of Fetuin on Lymphocyte Transformation Induced by One-way MLC
[2-"C]thymidine
MeantSDof four
experiments
￿
1.25
￿
61.1 t 30.4$
2.5
￿
85.3t 16.5$
* Compared with the amount of DNA synthesis observed in the absence of fetuin.
$ The difference between these values is not significant.
the precipitates thus formed in the presence of high fetuin:H-PHAP concentra-
tion ratios is reflected in the formation of high-mol-wt soluble complexes between
fetuin and H-PHAP in free solution at high fetuin:H-PHAP concentrationratios .
The gel diffusion experiments would support the conclusion that, in the presence
of a large excess of fetuin, each H-PHAP molecule combines with at least two
molecules of fetuin, and that some H-PHAP molecules may in fact combine with
more than two fetuin molecules. The L-PHAP molecule, on the other hand,
shows little, if any affinity for fetuin ; it lacks the ability to form agar gel
precipitates with fetuin, and during gel diffusion in the presence of a large fetuin
excess only 6-7% of the molecules in L-PHAP are shifted to significantly higher
molwt regions. This figure corresponds closely to an earlier estimate that we have
made (8%), on the basis of NH,-terminal amino acid analysis, of the degree to
which our L-PHAP preparations are contaminated by R subunits, presumably in
the form of the 3L-1R PHAP isomitogen (1). The low affinity which L-PHAP
displays for fetuin is reminiscent of its inability to combine with other serum
glycoproteins, and parallels as well its almost total inability to bind to or
agglutinate RBC (4). The L subunit of PHAP isomitogens fails to recognize
similar glycopeptide structures on fetuin and RBC membranes, which, however,
interact strongly with R subunit-containing PHAP molecules (H-PHAP) (6).
These observations lend reinforcement to previous evidence which suggests that
Exp. Fetuin
mg/ml
1 0
incorporation
(meantSD)
cpm
7,781 f 171
DNAsynthesis
inhibition
-
Pvalues
-
1 .25 462 f 510 94.1 <0.001*
2.5 217+ 54 97.2 <0.001*
2 0 8,710 1 313 - -
1.25 6,488 f 852 25.5 <0.02*
2.5 8 f 14 99.9 <0.001*
3 0 65,383 5,998 - -
1.25 34,074 t 4,975 47.9 <0.01*
2.5 13,463 t 10,420 79.4 <0.01*
4 0 27,350 931 - -
1.25 6,329 8,517 76.9 <0.02*
2.5 9,641 f 4,273 64.7 <0.01*9 Kornfeld, S. Personal communication.
STANLEY YACHNIN
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TABLE VII
The Interaction of
[125I]Fetuin with Lymphocytes
[1251]fetuin bound
* 5 x 108 cells incubated in 1.2 ml RPMI 1640 + 2.5 mg/ml [1251]fetuin (2.41 x 108 cpm).
$ ND, not done.
§Determined by latex particle ingestion.
114 x 108 cells incubated in 4 ml RPMI 1640 + 12.5% AB serum, containing 2.25 mg/ml fetuin and
0.25 mg/ml [1251]fetuin (8.64 x 105 cpm) . The values shown are the mean results of two separate
experiments.
the receptor for PHAP isomitogens on lymphocytes must be different from that
on RBC membranes or serum glycoproteins; that the ability of H-PHAP to bind
to and transform lymphocytes in a reflection of their hybrid structure; and that
such binding and transformation take place predominantly, if not exclusively,
through the L subunits ofH-PHAP. Thus, with increasing R:L subunit ratios, the
H-PHAP isomitogens become increasingly potent as hemagglutinins, but lose
their lymphocyte-transforming activity (4). The 4R H-PHAP isomitogen is
almost completely devoid of lymphocyte-transforming ability.3
Since fetuin can prevent binding of H-PHAP to lymphocytes, and can even
reverse a preexisting association between H-PHAP molecules and the lympho-
cyte membrane (9), while simultaneously lacking the ability to combine with the
L subunits which mediate such binding, it cannot truly be described as a
competitive inhibitor of the ability of H-PHAP to attach to lymphocyte
membrane receptors. Rather, the presence oflarge amounts offetuin would allow
for the formation of soluble complexes between fetuin and the H-PHAP
molecule, mediated by the strong affinity of the R subunit for the fetuin
glycopeptide. The H-PHAP molecules in such complexes may then be unable to
bind to lymphocytes through a process of steric hindrance, or possibly through
some allosteric conformational change in their L subunit lymphocyte-binding
site. The partial removal of previously bound H-PHAP from lymphocyte
membranes by the addition of fetuin may simply reflect the fact that the R
subunit on hybrid H-PHAP molecules already bound has a higher affinity forthe
Cell type Incubation
time
h
Mitogen
free
+ 5,ug/ml
L-PHAP
Short-term lymphocyte Lymphocytes 0.5 0.03 ND$
cultures*
Lymphocytes (85%) + 0.5 0.05 ND
monocytes (15%)§
Long-term lymphocyte Lymphocytes (77%)+ 1 0.005 0.007
cultures1l monocytes (23%)§ 18 0.003 0.009
42 0.002 0.005
66 0 0.019252
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fetuin glycopeptide than their L subunit has for the lymphocyte membrane
receptor. After their removal through such a process, reattachment of H-PHAP
molecules would be prevented by the mechanisms described above. These
processes would adequately explain the inhibition of H-PHAP-induced lympho-
cyte transformation by fetuin and would also be consistent with the observation
that the inhibitory effects of fetuin may be partially overcome by increments in
the H-PHAP stimulating dose, since the new equilibrium reached in the
competition between fetuin-R subunit and lymphocyte-L subunit associations
would result in a greater amount of H-PHAP bound to, and stimulating,
lymphocytes.
Since CON-A has also been shown to react strongly with a variety of serum
glycoproteins (16) the mechanism by which fetuin inhibits its mitogenic action
may resemble that described for H-PHAP. While we can say little about the
physical interaction between PWM and fetuin, in the case of L-PHAP it is
doubtful that the weak interaction it manifests with fetuin would suffice to
account for the ability of the latter to inhibit L-PHAP lymphocyte -mitogenic
activity. Although the mitogenic activity of L-PHAP at moderate concentrations
(4-5 u,g/ml) is significantly less inhibited by 1.25 mg/ml fetuin than that of
H-PHAP, at a fetuin concentration of 2.5 mg/ml this difference is largely
abolished, and cannot be explained by nonspecific toxic effects of fetuin upon the
lymphocytes, for reasons which have already been discussed (9). These observa-
tions raise the possibility that fetuin has some direct effect upon the lymphocyte
itself which is able to suppress its response to mitogenic stimuli. Theparadoxical
difference between H- and L-PHAP with respect to the ability of increasing
mitogen concentrations to overcome this inhibitory effect of fetuin would also
suggest that simple mitogen binding cannot account for the inhibitory, effects of
fetuin upon L-PHAP-induced lymphocyte transformation, since these effects
would then be expected to parallel those observed with H-PHAP. It is also
pertinent to note that the ability of fetuin to inhibit lymphocyte transformation
by the two PHAP mitogens is significantly different only at the lowest mitogen
dose, and then only at a fetuin concentration of 1.25 mg/ml. At all other
mitogen:fetuin concentration ratios the inhibitory effects of fetuin for L- and
H-PHAP are not significantly different. The reversal of fetuin inhibition by
increasing H-PHAP concentrations reaches a plateau at 15.4 Ag/ml; further
increase in the H-PHAP dose does . not result in a proportional fall in the
inhibitory effects of fetuin . Thus it appears that, in the case of H-PHAP, the
inhibitory effects of fetuin may initially depend upon simple competition for
mitogen through soluble complex formation; but a second process resembling
that seen with L-PHAP may also play a role in preventing transformation. The
paradoxical increase in the ability of fetuin to inhibit lymphocyte transformation
at higher L-PHAP doses also suggests that the direct inhibitory effect of fetuin on
lymphocyte transformation is in some way related to, and dependent upon, the
intensity of the mitogenic stimulus.
The experiments with ATS also support the theory that fetuin can directly
inhibit the lymphocyte response to mitogens, unless fetuin happened to share an
immunologically similar structural determinant with human fetal thymocytes.
However, the most compelling evidence for a direct role of fetuin in suppressingSTANLEY YACHNIN
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lymphocyte responses to mitogenic stimuli comes from a consideration of its
effect upon the one-way MLC, where no soluble mitogenic material with a
possible independent affinity for the fetuin molecule is involved . In whatever
fashion fetuin inhibits the MLC, it does not seem to involve a firm, irreversible
association with either the stimulating or responding cell populations, as our
experiments with [1211]fetuin demonstrate.
Fetuin is the bovine representative of a class of proteins, the a-fetoproteins,
which are present in fetal sera but lacking in homospecific adult sera, and whose
role in fetal life is not well understood. The analogous human a-fetoprotein is
present in near-maximal concentrations (approximately 200 mg/100 ml) by the
10th wk of gestation. This high serum level is maintained until approximately 22
weeks' gestation and thereafter falls progressively to <5 mg/100 ml near term
(17) . One striking property of fetuin is its ability to act as a serum substitute and
growth factor for many mammalian cell lines in tissue culture (18) . It has also
been reported to stimulate the proliferation of hematopoietic stem cells when
injected into mice (19) . Thus it may play a general role as a supporter of, and
stimulus for, the high rate of cell proliferation characteristic of fetal develop-
ment. In this context, its inhibitory effect upon in vitro lymphocyte proliferation
may reflect a second highly specialized function in fetal life essential for
successful embryonic development, namely, the development of immunologic
tolerance to autologous antigens. Its role in this process may rest upon three
aspects related to our in vitro observations: (a) Fetuin does not adversely affect
resting lymphocyte viability. (b) It is able to inhibit the proliferation of
lymphocytes in the presence of a mitogenic stimulus. (c) Its inhibitory effect
upon lymphocyte proliferation is proportional to the intensity of the mitogenic
stimulus and might conceivably contribute to cell death should the stimulus be
strong enough . These premises would allow for the preservation of the repertoire
of specificities required of an intact, universally responsive, postnatal immune
system, while at the same time suppressing, and possibly aiding in the
elimination of, those lymphocyte clones subjected to sustained and intensive
provocation by autoantigens in fetal life. Further experiments are in progress to
test the validity of these hypotheses .
The capacity of fetuin for inhibiting the proliferative response of lymphocytes
to a variety of mitogenic stimuli is reminiscent of the similar effects of another
serum a-protein, the immunoregulatory a-globulin (IRA) (20) . Even though IRA
also possesses the ability to combine with and precipitate H-PHAP, but not
L-PHAP, it is able to suppress lymphocyte transformation by both mitogens
approximately to the same degree (21) . A variety of studies has made clear that
the immunosuppressive functions of IRA depend upon some direct, but poorly
understood effect which it exerts upon the lymphocyte itself (22, 23), and that it
is capable of such diverse actions as the inhibition of the lymphocyte mitogenic
response to phytomitogens and antilymphocyte serum, as well as to antigens and
to the mixed leukocyte reaction (22) . In addition, IRA inhibits antibody
formation and skin graft rejection when it is administered to mice before
appropriate challenge (24, 25). While we do not understand the precise
mechanism by which a-glycoproteins such as fetuin or IRA inhibit lymphocyte
responsiveness, the special ability which fetuin possesses to perturb the limiting254
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membrane of macrophages and to stimulate pinocytosis may offer a clue (26),
since the initial step in the immune response, or in the activation of lymphocytes
by phytomitogens, depends upon the ability of mitogens or antigen to combine
with membrane receptors. Derangement of lymphocyte membrane stability, or
preventing access to crucial sites on the lymphocyte cell surface early in the
course of mitogen action via a "blindfolding" effect (21, 23), by a substance such
as fetuin, may interfere with these initial steps.
Fetuin, the bovine a-fetoprotein, contains glycopeptide sequences similar to
those found on red cells. As a result, it is capable of strong physical interaction
with the phytohemagglutinin isomitogens (H-PHAP) which possess two or more
R (red cell binding) subunits as part of their tetrameric structures. Fetuin shows
little or no interaction with L-PHAP, a phytohemagglutinin made up of four L
subunits which also lack red cell affinity. Despite these differences fetuin is able
to inhibit both H- and L-PHAP-induced lymphocyte transformation and is also
capable of inhibiting the mitogenic effects of pokeweed mitogen, concanavalin A,
antithymocyte antiserum, and the one-way mixed lymphocyte culture. In the
case of L-PHAP, the inhibitory effect of fetuin is proportional to the intensity of
the mitogenic stimulus. The inhibitory effects of fetuin upon lymphocyte
transformation may result from perturbation or "blindfolding" of the cell
membrane in a manner analogous to other immunosuppressive serum a-
globulins. a-Fetoproteins may play an immunoregulatory role during fetal
development.
The expert technical assistance of Mrs. Janine Raymond is deeply appreciated. The author thanks
Dr. John Hopper and Dr. Joseph Baron for their help in preparing ATS andradioiodinated PHAP and
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